Latest Merck Stories

redOrbit Staff & Wire Reports - Your Universe Online Liptruzet, a combination drug developed by Merck that has been found to lower a patient’s low-density lipoprotein (LDL) cholesterol levels, has been approved by the US Food and Drug Administration (FDA). According to MedPage Today Cardiology Editor Chris Kaiser, Liptruzet is a combination of the drugs ezetimibe and atorvastatin and has been approved for the treatment of hyperlipidemia, a condition characterized by abnormally...

http://www.DrugRisks.com is the most helpful resource on the web for prescription medication alerts, side effects and legal news. Visit us today. New York, NY (PRWEB) May 04, 2013 The IUD safety advocates at DrugRisks.com are announcing new updates to the site for women who have used the vaginal ring contraceptive NuvaRing. This week, device maker Merck released records indicating use of the device have slowed since the end of last year*. DrugRisks was designed to give patients using...

The DrugRisk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com St. Louis, MO (PRWEB) May 03, 2013 The birth control safety advocates at DrugRisk.com are announcing updated news for women who have used the contraceptive NuvaRing. Financial records released by Merck this week show sales of the device have slowed from the end of last year*. The goal of DrugRisk is to improve the safety of...

Merck's Bridgette P. Heller receives cover feature, exclusive behind-the-scenes interview and photographs NEW YORK, May 1, 2013 /PRNewswire/ -- PHARMACEUTICAL EXECUTIVE magazine's April cover story profiles Bridgette P. Heller, executive vice president at Merck, president of Merck Consumer Care and the Healthcare Businesswomen's Association (HBA) 2013 Woman of the Year. For the sixth year in a row, PHARMACEUTICAL EXECUTIVE, the industry's premier publication, highlights HBA's choice...

CHICAGO, April 30, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Merck & Co. Inc. (NYSE:MRK), GlaxoSmithKline (NYSE:GSK), VIVUS Inc. (Nasdaq:VVUS), Santarus, Inc. (Nasdaq:SNTS) and Celgene Corporation (Nasdaq:CELG). (Logo:...

HONG KONG, April 19, 2013 /PRNewswire/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports for the following companies: KeyCorp (NYSE:KEY), Procter & Gamble (NYSE:PG), Cypress Semiconductor (NASDAQ:CY), Research In Motion (NASDAQ:BBRY), Goldcorp (NYSE:GG), and Merck (NYSE:MRK). (Logo: http://photos.prnewswire.com/prnh/20130417/HK96241LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your browser.) Report...

CHICAGO, April 17, 2013 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRK, NTAP, CSX, THRX, and UNXL. (Photo: http://photos.prnewswire.com/prnh/20120712/CG39046) To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at http://www.investorsobserver.com/pr/41620132 (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks:...

All amounts are in US dollars (unless otherwise mentioned) QUÉBEC CITY, April 17, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide(®) product. The principal effect of such agreements is to transfer manufacturing rights and to grant a manufacturing license...

VANCOUVER, British Columbia, April 17, 2013 /PRNewswire/ -- Xenon announced that Merck, known as MSD outside the United States and Canada, through an affiliate, has exercised its option to exclusively license small molecule compounds for a novel target for the potential treatment of cardiovascular disease. In 2009, Xenon and Merck entered into a strategic alliance where Xenon employed its human clinical genetics platform to validate novel cardiovascular targets and collaborated on the...

PHILADELPHIA, April 15, 2013 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced that six new pharmaceutical companies have joined as members of the independent non-profit entity formed to assess, refine and create processes to bring innovative new medicines to the public faster. The addition of the new members to TransCelerate marks a major milestone since the organization's founding by ten healthcare and pharmaceutical companies in September 2012. The new...